Distributions of Intravenous Injected Iodine Nanoparticles in Orthotopic U87 Human Glioma Xenografts Over Time and Tumor Therapy

Abstract

Aim: To analyze the localization, distribution and effect of iodine nanoparticles (INPs) on radiation therapy (RT) in advanced intracerebral gliomas over time after intravenous injection. Materials & methods: Luciferase/td-tomato expressing U87 human glioma cells were implanted into mice which were injected intravenously with INPs. Mice with gliomas were followed for tumor progression and survival. Immune-stained mouse brain sections were examined and quantified by confocal fluorescence microscopy. Results: INPs injected intravenously 3 days prior to RT, compared with 1 day, showed greater association with CD31-staining structures, accumulated inside tumor cells more, covered more of the tumor cell surface and trended toward increased median survival. Conclusion: INP persistence and redistribution in tumors over time may enable greater RT enhancement and clinically relevant hypo-fractionated-RT and may enhance INP efficacy.

Keywords::

• distribution
• fractionated radiation therapy
• glioma radiotherapy
• iodine nanoparticles
• microlocalization
• radiation therapy

Financial & competing interests disclosure

This work was supported in part by NIH grant 1R43CA192702 and the Connecticut Brain Tumor Alliance. J Hainfeld is a part owner of Nanoprobes, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Acknowledgments

We dedicate this paper to the memory of T Gammer-Fanning, founder of the Connecticut Brain Tumor Alliance.

Additional information

Funding

This work was supported in part by NIH grant 1R43CA192702 and the Connecticut Brain Tumor Alliance. J Hainfeld is a part owner of Nanoprobes, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.